United Therapeutics Corp. (UTHR)
487.61
-2.63
(-0.54%)
USD |
NASDAQ |
Sep 04, 16:00
487.66
+0.06
(+0.01%)
After-Hours: 20:00
United Therapeutics SG&A Expense (TTM) : 644.60M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 644.60M |
| March 31, 2026 | 631.50M |
| December 31, 2025 | 645.00M |
| September 30, 2025 | 627.50M |
| June 30, 2025 | 596.60M |
| March 31, 2025 | 572.90M |
| December 31, 2024 | 529.10M |
| September 30, 2024 | 508.00M |
| June 30, 2024 | 498.00M |
| March 31, 2024 | 481.70M |
| December 31, 2023 | 456.00M |
| September 30, 2023 | 446.10M |
| June 30, 2023 | 437.90M |
| March 31, 2023 | 408.80M |
| December 31, 2022 | 404.00M |
| September 30, 2022 | 384.10M |
| June 30, 2022 | 372.30M |
| March 31, 2022 | 369.20M |
| December 31, 2021 | 358.70M |
| September 30, 2021 | 352.30M |
| June 30, 2021 | 336.40M |
| March 31, 2021 | 314.00M |
| December 31, 2020 | 296.70M |
| September 30, 2020 | 315.90M |
| June 30, 2020 | 340.10M |
| Date | Value |
|---|---|
| March 31, 2020 | 312.20M |
| December 31, 2019 | 336.20M |
| September 30, 2019 | 310.20M |
| June 30, 2019 | 320.90M |
| March 31, 2019 | 364.40M |
| December 31, 2018 | 265.80M |
| September 30, 2018 | 345.70M |
| June 30, 2018 | 282.80M |
| March 31, 2018 | 267.10M |
| December 31, 2017 | 330.10M |
| September 30, 2017 | 310.50M |
| June 30, 2017 | 363.40M |
| March 31, 2017 | 368.20M |
| December 31, 2016 | 316.80M |
| September 30, 2016 | 325.86M |
| June 30, 2016 | 208.48M |
| March 31, 2016 | 246.27M |
| December 31, 2015 | 452.61M |
| September 30, 2015 | 384.58M |
| June 30, 2015 | 604.37M |
| March 31, 2015 | 562.41M |
| December 31, 2014 | 381.29M |
| September 30, 2014 | 457.93M |
| June 30, 2014 | 349.54M |
| March 31, 2014 | 352.87M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Liquidia Corp. | 192.66M |
| MannKind Corp. | 341.36M |
| Vertex Pharmaceuticals, Inc. | 2.008B |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Savara, Inc. | 56.71M |